As of November 13, 2026, 4 holders' latest Schedule 13D or 13G filings report owning 5% or more of Helus Pharma Inc. The largest reported stake is Venrock Healthcare Capital Partners III, L.P.'s, at 9.9%. 19 filings are on record since August 14, 2025 (Schedule 13G, November 7, 2025).
Sell to companies like Helus Pharma Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Reporting person: Adage Capital Management, L.P. · Sole voting: 0 · Shared voting: 5,479,250 · Sole dispositive: 0 · Shared dispositive: 5,479,250 · SCHEDULE 13G/A, 2026-11-12
- · Reporting person: Integrated Core Strategies (US) LLC · Sole voting: 0 · Shared voting: 688,622 · Sole dispositive: 0 · Shared dispositive: 688,622 · SCHEDULE 13G/A, 2026-11-12
- · Reporting person: Glavine Paul · Sole voting: 4,071,252 · Shared voting: 336,204 · Sole dispositive: 4,071,252 · Shared dispositive: 336,204 · SCHEDULE 13D, 2026-09-09
- · Reporting person: So Eric H. L. · Sole voting: 4,370,278 · Shared voting: 53,616 · Sole dispositive: 4,370,278 · Shared dispositive: 53,616 · SCHEDULE 13D, 2026-09-09
- · Reporting person: Sirenia Capital Management LP · Sole voting: 0 · Shared voting: 3,029,500 · Sole dispositive: 0 · Shared dispositive: 3,029,500 · SCHEDULE 13G/A, 2026-08-14
Helus Pharma Inc. has 19 Schedule 13D or 13G filings on record since 2025-08-14. 4 holders' latest filing reports 5% or more of common shares, no par value. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| Venrock Healthcare Capital Partners III, L.P. | 9.9% | 5,111,412 | SCHEDULE 13G, 2025-11-07 | 2025-10-31 |
| Adage Capital Management, L.P. | 7.48% | 5,479,250 | SCHEDULE 13G/A, 2026-11-12 | 2026-09-30 |
| 5.8% | 4,407,456 | SCHEDULE 13D, 2026-09-09 | 2026-09-01 | |
| 5.8% | 4,423,894 | SCHEDULE 13D, 2026-09-09 | 2026-09-01 | |
| Orbimed Capital LLC | 4.9% | 2,422,600 | SCHEDULE 13G, 2026-02-17 | 2025-12-31 |
| Sirenia Capital Management LP | 4.8% | 3,029,500 | SCHEDULE 13G/A, 2026-08-14 | 2026-06-30 |
| Deep Track Capital, LP | 4.74% | 2,391,505 | SCHEDULE 13G/A, 2026-02-13 | 2025-12-31 |
| Point72 Asset Management, L.P. | 1.4% | 686,669 | SCHEDULE 13G/A, 2026-05-15 | 2026-03-31 |
| Millennium Management LLC | 1.4% | 1,018,972 | SCHEDULE 13G/A, 2026-11-12 | 2026-09-30 |
| Tang Capital Management, LLC | 0% | 0 | SCHEDULE 13G/A, 2026-02-17 | 2025-12-31 |
Holding shares or following this stake? See who's behind Helus Pharma Inc. and the warning signs.
Free to see. No signup.
Keep reading
More on Helus Pharma Inc. and the records around it.
Helus Pharma Inc. elsewhere on the record
Companies that share a holder
- Sirenia Capital Management LP also filed stake reports on 19 other companies: Alto Neuroscience, Inc. (Aug 2026), ANAPTYSBIO, INC (Aug 2026), Design Therapeutics, Inc. (Aug 2026)
- TANG CAPITAL MANAGEMENT, LLC also filed stake reports on 33 other companies: EyePoint, Inc. (Oct 2026), Skye Bioscience, Inc. (Oct 2026), Nano Dimension Ltd. (Aug 2026)
- Venrock Healthcare Capital Partners III, L.P. also filed stake reports on 34 other companies: Entera Bio Ltd. (Oct 2026), Lycia Therapeutics, Inc. (Oct 2026), Frazier Life Sciences Acquisition Corp. II (Oct 2026)
Watch Helus Pharma Inc.
Get an email when Helus Pharma Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Helus Pharma Inc.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Helus Pharma Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Helus Pharma Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
19 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| Adage Capital Management, L.P. | 0 | 5,479,250 | 0 | 5,479,250 | SCHEDULE 13G/A, 2026-11-12 |
| Robert Atchinson | 0 | 5,479,250 | 0 | 5,479,250 | SCHEDULE 13G/A, 2026-11-12 |
| Phillip Gross | 0 | 5,479,250 | 0 | 5,479,250 | SCHEDULE 13G/A, 2026-11-12 |
| Glavine Paul | 4,071,252 | 336,204 | 4,071,252 | 336,204 | SCHEDULE 13D, 2026-09-09 |
| PLG Family Trust | 0 | 336,204 | 0 | 336,204 | SCHEDULE 13D, 2026-09-09 |
| So Eric H. L. | 4,370,278 | 53,616 | 4,370,278 | 53,616 | SCHEDULE 13D, 2026-09-09 |
| So Tina | 0 | 53,616 | 0 | 53,616 | SCHEDULE 13D, 2026-09-09 |
| Sirenia Capital Management LP | 0 | 3,029,500 | 0 | 3,029,500 | SCHEDULE 13G/A, 2026-08-14 |
| Alex Silverstein | 0 | 3,029,500 | 0 | 3,029,500 | SCHEDULE 13G/A, 2026-08-14 |
| Integrated Core Strategies (US) LLC | 0 | 688,622 | 0 | 688,622 | SCHEDULE 13G/A, 2026-11-12 |
| Millennium Management LLC | 0 | 1,018,972 | 0 | 1,018,972 | SCHEDULE 13G/A, 2026-11-12 |
| Millennium Group Management LLC | 0 | 1,018,972 | 0 | 1,018,972 | SCHEDULE 13G/A, 2026-11-12 |
| Israel A. Englander | 0 | 1,018,972 | 0 | 1,018,972 | SCHEDULE 13G/A, 2026-11-12 |
The latest filing identifies Helus Pharma Inc. by CUSIP 423492107 and gives its principal executive office as 100 KING STREET WEST, SUITE 5600, TORONTO, ONTARIO (SCHEDULE 13G/A, 2026-11-12).
Source of funds (Item 3)
The Reporting Person's holdings were acquired by the Reporting Persons using personal funds or through company employee incentive awards. PLG Family Trust's holdings were acquired using working capital of PLG Family Trust.Glavine Paul, SCHEDULE 13D, 2026-09-09
The holdings were acquired by the Reporting Persons using personal funds or through company employee incentive awards.So Eric H. L., SCHEDULE 13D, 2026-09-09
Purpose of Transaction (Item 4)
Glavine Paul
Investment purposes and Issuer employee incentive awardsItem 4 of the SCHEDULE 13D filed 2026-09-09
So Eric H. L.
Investment and company employee incentive awardsItem 4 of the SCHEDULE 13D filed 2026-09-09
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-08-14 | Point72 Asset Management, L.P. | 7% | SCHEDULE 13G/A |
| 2025-10-29 | Deep Track Capital, LP | 3.97% | SCHEDULE 13G/A |
| 2025-11-04 | Deep Track Capital, LP | 6.09% | SCHEDULE 13G |
| 2025-11-07 | Venrock Healthcare Capital Partners III, L.P. | 9.9% | SCHEDULE 13G |
| 2025-11-14 | Point72 Asset Management, L.P. | 9.9% | SCHEDULE 13G/A |
| 2026-02-13 | Deep Track Capital, LP | 4.74% | SCHEDULE 13G/A |
| 2026-02-17 | Orbimed Capital LLC | 4.9% | SCHEDULE 13G |
| 2026-02-17 | Tang Capital Management, LLC | 0% | SCHEDULE 13G/A |
| 2026-03-26 | Millennium Management LLC | 4.8% | SCHEDULE 13G |
| 2026-04-10 | Millennium Management LLC | 5% | SCHEDULE 13G |
| 2026-04-22 | Millennium Management LLC | 5.7% | SCHEDULE 13G/A |
| 2026-05-15 | Sirenia Capital Management LP | 7.2% | SCHEDULE 13G |
| 2026-05-15 | Point72 Asset Management, L.P. | 1.4% | SCHEDULE 13G/A |
| 2026-08-12 | Adage Capital Management, L.P. | 5.29% | SCHEDULE 13G |
| 2026-08-14 | Sirenia Capital Management LP | 4.8% | SCHEDULE 13G/A |
| 2026-09-09 | Glavine Paul | 5.8% | SCHEDULE 13D |
| 2026-09-09 | So Eric H. L. | 5.8% | SCHEDULE 13D |
| 2026-11-12 | Adage Capital Management, L.P. | 7.48% | SCHEDULE 13G/A |
| 2026-11-12 | Millennium Management LLC | 1.4% | SCHEDULE 13G/A |
Questions about who owns Helus Pharma Inc.
Who owns Helus Pharma Inc.?
On this page, 4 holders' latest ownership filings report 5% or more of Helus Pharma Inc.: Venrock Healthcare Capital Partners III, L.P. (9.9%, Schedule 13G, filed 2025-11-07), Adage Capital Management, L.P. (7.48%, Schedule 13G/A, filed 2026-11-12), Glavine Paul (5.8%, Schedule 13D, filed 2026-09-09) and So Eric H. L. (5.8%, Schedule 13D, filed 2026-09-09).
Who are the largest shareholders of Helus Pharma Inc.?
By the share each holder's latest filing reports, the largest holders of Helus Pharma Inc. on this page are Venrock Healthcare Capital Partners III, L.P. (9.9%), Adage Capital Management, L.P. (7.48%) and Glavine Paul (5.8%).
When did Venrock Healthcare Capital Partners III, L.P. buy into Helus Pharma Inc.?
The filings give report dates, not purchase dates. The earliest filing from Venrock Healthcare Capital Partners III, L.P. on this page is the Schedule 13G, filed 2025-11-07, reporting 9.9%.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 19 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Tools for this story
Each opens in a new tab, filled in for Helus Pharma Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.
